Calcitonin adjunct therapy significantly reduces phantom limb pain intensity and distress
Background
Managing phantom limb pain (PLP), a chronic and often debilitating condition affecting individuals post-amputation, remains a significant clinical challenge. Current treatments, including opioids, antidepressants, and anticonvulsants, often provide incomplete relief and carry substantial side effect profiles. There's a critical need for effective, non-opioid adjunct therapies. Calcitonin, a hormone primarily known for its role in calcium regulation and bone metabolism, also exhibits analgesic properties, potentially by modulating central pain pathways. This study explores its utility as an adjunctive treatment for acute PLP.
Study Design
This retrospective cohort study analyzed 35 patients who received Calcitonin for at least 3 days (Day 1-3) between 2017 and 2023 following lower limb amputation. Researchers collected demographic data and pain ratings (intensity, distress, interference) at Day 0 (pre-intervention) and Day 7 (post-intervention). Data analysis utilized descriptive statistics and paired t-tests to assess changes in pain outcomes. A two-way repeated measures ANOVA compared outcomes between patients with and without diabetes. The primary endpoints included changes in pain intensity, pain-related distress, and perceived pain relief scores.
Results
Calcitonin treatment was associated with significant reductions in several pain outcomes. Mean pain intensity decreased from 6.41 to 5.24 (Cohen's d = 0.66; p=0.02), representing an 18.2% reduction. Pain-related distress also significantly decreased from 5.85 to 4.81 (Cohen's d = 0.71; p=0.014), a 17.7% reduction. Patients reported increased perceived pain relief scores, which rose from 33.69 to 58.21 (Cohen's d = 0.53; p=0.035). No significant differences in pain intensity or distress were observed between patients with and without diabetes. Importantly, there was no significant change in the Oral Morphine Equivalent Daily Dose (p=0.94), suggesting calcitonin provided pain relief without increasing opioid reliance.
Calcitonin significantly reduced perceived pain intensity by 18.2% and pain-related distress by 17.7% within seven days of treatment initiation.
Key Findings
- Calcitonin reduced mean pain intensity from 6.41 to 5.24 (Cohen's d = 0.66; p=0.02).
- Pain-related distress decreased from 5.85 to 4.81 (Cohen's d = 0.71; p=0.014).
- Perceived pain relief scores increased from 33.69 to 58.21 (Cohen's d = 0.53; p=0.035).
- No significant difference in pain outcomes was observed between diabetic and non-diabetic patients.
- No significant change in
Oral Morphine Equivalent Daily Dosewas noted (p=0.94).
Why It Matters
This study provides evidence that Calcitonin can be a valuable non-opioid adjunct for acute phantom limb pain (PLP) management in the immediate post-amputation period. The observed reductions in pain intensity and distress, coupled with increased patient-reported relief, suggest a practical benefit. Given the challenges of opioid dependence and side effects, integrating calcitonin into early post-amputation pain protocols could improve patient outcomes and reduce reliance on conventional analgesics. While this is a retrospective study, the findings support further investigation into calcitonin's role in a multimodal pain management strategy for PLP, potentially leading to more comprehensive and safer treatment options for amputees.
calcitonin
phantom-limb-pain
pain-management
amputation
retrospective-study
cohort-study